More than half of patients getting platinum-based chemotherapy develop lasting nerve damage from the treatment itself, pain, numbness, burning, and heightened sensitivity to cold that can persist for years. It’s common enough, and severe enough, that it regularly forces oncologists to cut chemotherapy doses or stop treatment early, even when the cancer is still responding. There’s never been an effective way to prevent it. A study published September 3 in Science, led by researchers at MD Anderson Cancer Center, found that two doses of psilocybin, given just before chemotherapy starts, stopped this nerve damage from developing at all in mice, and the protection lasted through six full treatment cycles.
What breaks in the nerves, and what psilocybin fixes
Chemotherapy drugs like cisplatin damage nerve cells by depleting their mitochondria, the small structures that generate a cell’s energy, specifically in the long, thin extensions of the nerve that reach out to the skin. Without enough mitochondria able to travel to where the energy is needed, those nerve endings start to fail. The MD Anderson team, co-led by Moran Amit and Patrick Dougherty, found that psilocybin doesn’t restore how much total energy the mitochondria can produce. Instead, it keeps the mitochondria moving and properly positioned within the nerve fiber, so the energy being made reaches the parts of the cell that need it. In mice, that was enough: two doses of psilocybin, given nine days and two days before the first chemotherapy session, completely prevented the animals from developing pain and cold sensitivity, and the effect held up through six separate rounds of chemotherapy.
Why this isn’t just another version of psilocybin’s psychiatric mechanism
Almost everything written about psilocybin’s therapeutic potential, cancer-related distress and pain conditions like fibromyalgia included, traces back to its effects on serotonin signaling in the brain, either recalibrating central pain processing or reducing the psychological distress that makes pain feel worse. This finding is different in kind, not degree. The protection here happens directly at the nerve, through a serotonin receptor, 5-HT2A, acting locally to preserve cellular transport machinery, not through any effect on mood, perception, or brain-wide network activity. It’s a separate mechanism from anything else in psilocybin’s therapeutic story so far, which matters because it means this potential use doesn’t depend on whether the brain-based mechanisms driving psilocybin’s psychiatric effects turn out to hold up in larger trials. The same study did separately report psilocybin normalizing certain markers of brain activity in the mice, but that finding sits apart from the neuropathy-prevention mechanism itself, which the researchers traced specifically to the nerve.
Why the human tissue confirmation matters more than the mouse data alone
Mouse studies of nerve protection often don’t translate to humans, a real limit worth taking seriously with any psychedelic finding built on animal models alone. This study went further than most: the researchers tested human donor sensory neurons and skin biopsies from real patients, and found the same serotonin receptor to mitochondrial-trafficking pathway present and functional in human tissue, not just mouse tissue. That doesn’t guarantee the drug will work the same way in a living patient going through chemotherapy, but it substantially raises the odds that the underlying biology is real and relevant to humans, not an artifact of the mouse model.
The detail that determines whether this could ever be used
A neuroprotective drug that also protects cancer cells from chemotherapy would be worse than useless. The study specifically tested this, and found psilocybin’s protection of healthy nerve tissue did not reduce chemotherapy’s ability to kill tumor cells in the same animals. That’s the single most important safety finding in the whole study for any real-world application, since it’s the one result that could have ended this idea immediately if it had gone the other way.
What happens next
These findings are already the basis for a registered Phase 2 trial, NeuroGuard, testing psilocybin given before and during chemotherapy across multiple cancer types, specifically to see whether what worked in mice and human tissue produces a measurable reduction in nerve damage in cancer patients. That trial hasn’t reported results yet. Separately, the same research group is running trials testing psilocybin-assisted therapy for anxiety and depression in cancer patients, a completely different application built on the more familiar psychiatric mechanism, meaning MD Anderson now has two independent psilocybin research tracks running in the same patient population for two unrelated reasons.
What this doesn’t prove yet
This is preclinical and translational research, mouse models and human tissue samples, not a clinical trial in actual chemotherapy patients. Nothing here confirms psilocybin prevents neuropathy in a real cancer patient, only that the mechanism appears to exist and appears to translate to human cells. The specific dosing schedule used in mice, timed doses before chemotherapy begins, may or may not be the right approach in humans, and how psilocybin’s well-known perceptual effects would be managed in patients undergoing cancer treatment, rather than a dedicated psychiatric session, remains an open practical question the Phase 2 trial will need to address directly.